Epac activation with 8CPT-AM induced RLC phosphorylation in the perfused hearts. by Yoshiki Ohnuki (576298)

Subjects:

Changes in AL (A) and SE (B) according to the treatment time estimation curve in patients given 0.125% atropine. by Zi-Rong Chen (9227618)

Subjects:

Flow diagram of the patient selection into the final analysis. by Zi-Rong Chen (9227618)

Subjects:

Patients’ demographics and clinical parameters. by Zi-Rong Chen (9227618)

Subjects:

Associations between demographic variables, In4_SED and SE changes at 6 and 12 months after 4_SED (<i><i>n</i></i> = 80). by Zi-Rong Chen (9227618)

Subjects:

Table 2 - Early identification of the efficacy of 0.125% atropine treatment for children with Myopia: A prospective pilot study by Zi-Rong Chen (9227618)

Subjects:

Functional characterization of skinned myocardium prepared from Epac1TG. by Yoshiki Ohnuki (576298)

Subjects:

Effects of chronic ISO infusion on cardiac function in Epac1TG. by Yoshiki Ohnuki (576298)

Subjects:

(a to g) Administration of vitamin D3 increased serum phosphorus and triglycerides. by Vidya G. Bettada (22208808)

“…Analyses of serum cholesterol, HDL and triglycerides also showed a non-significant decrease in the serum HDL level upon treatment with 125 µg/Kg vitamin D3, but a noticeable increase in the serum triglyceride level was observed with 125 µg/Kg of vitamin D3.…”

Spearman’s correlation matrix of weather conditions, both mean (x̄) and maximum, against daily number of visits to the water trough, mean water intake per visit, and mean water int... by M. Jordana Rivero (14610947)

Blood Pressure and LDL-C During Follow-up. by Karl Ingard (22582091)

Subjects:

Median EQ-5D-3L index values during 5 years of follow-up. by Karl Ingard (22582091)

Subjects:

Baseline Characteristics of Included Patients. by Karl Ingard (22582091)

Subjects:

Subgroup Analysis of the Occurrence of Secondary Endpoints. by Karl Ingard (22582091)

Subjects:

Study flow chart. by Karl Ingard (22582091)

Subjects:

Kaplan-Meier curve of the primary outcome. by Karl Ingard (22582091)

Subjects:

Number of Patients Who Reached the Primary and Secondary Endpoints During Follow-up. by Karl Ingard (22582091)

Subjects:

Subgroup Analysis of the Occurrence of the Primary Endpoint and Its Components. by Karl Ingard (22582091)

Subjects:

Tetrandrine decreases Mtb antigen presentation. by Elham Karamooz (2584474)

Baseline patient characteristics. by Oscar F. C. van den Bosch (22184246)

Subjects: